Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Stock Has Average Target Price of $9.40 According to Brokerages

Tvardi Therapeutics, Inc. (NASDAQ:TVRD) has received a consensus recommendation of “Moderate Buy” from the eight research firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, six have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $9.40.

A number of equities research analysts have issued reports on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Tvardi Therapeutics in a research report on Friday, October 2nd. Wall Street Zen downgraded shares of Tvardi Therapeutics from a “sell” rating to a “strong sell” rating in a report on Sunday, November 1st. Lucid Cap Mkts raised Tvardi Therapeutics to a “strong-buy” rating in a research report on Tuesday, September 8th. BTIG Research cut their price objective on shares of Tvardi Therapeutics to $5.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. Finally, Chardan Capital assumed coverage on shares of Tvardi Therapeutics in a research note on Tuesday, October 20th. They set a “buy” rating for the company.

Institutional Investors Weigh In On Tvardi Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in Tvardi Therapeutics during the 2nd quarter worth $181,000. Susquehanna International Group LLP bought a new stake in shares of Tvardi Therapeutics in the 2nd quarter valued at about $63,000. Finally, GSA Capital Partners LLP bought a new stake in Tvardi Therapeutics during the second quarter worth about $34,000. Hedge funds and other institutional investors own 44.66% of the company’s stock.

Tvardi Therapeutics Stock Performance

Shares of NASDAQ TVRD opened at $0.96 on Friday. The firm has a market cap of $12.78 million, a price-to-earnings ratio of -0.34 and a beta of 0.37. Tvardi Therapeutics has a 52 week low of $0.77 and a 52 week high of $5.69. The business’s 50-day simple moving average is $1.28 and its 200-day simple moving average is $2.68.

Tvardi Therapeutics (NASDAQ:TVRD) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04). As a group, equities research analysts forecast that Tvardi Therapeutics will post -2.23 earnings per share for the current year.

About Tvardi Therapeutics

Tvardi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases involving abnormal STAT3 signaling. STAT3 is a protein that can contribute to tumor growth, treatment resistance and immune suppression, making it a potential target for drug development.

The company’s lead investigational product is TTI-101, an orally administered small-molecule inhibitor designed to block STAT3 activity. Tvardi is evaluating TTI-101 in clinical studies for solid tumors, including hepatocellular carcinoma and other advanced cancers.